Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
Four-repeat tauopathies
corticobasal degeneration
diagnostic criteria
progressive supranuclear palsy
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
10
06
2019
revised:
17
08
2019
accepted:
03
09
2019
pubmed:
2
10
2019
medline:
18
12
2020
entrez:
2
10
2019
Statut:
ppublish
Résumé
The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category "probable 4-repeat (4R)-tauopathy" for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration. To validate the accuracy of these clinical criteria for "probable 4R-tauopathy" to predict underlying 4R-tauopathy pathology. Diagnostic accuracy for 4R-tauopathies according to the established criteria was estimated retrospectively in autopsy-confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R-tauopathies), and Parkinson's disease, multiple system atrophy, and frontotemporal lobar degeneration (grouped as non-4R-tauopathies). We identified 250 cases with progressive supranuclear palsy (N = 195) and corticobasal degeneration (N = 55) and with and non-4R-tauopathies (N = 161). Sensitivity and specificity of "probable 4R-tauopathy" was 10% and 99% in the first year and 59% and 88% at final record. The new diagnostic category "probable 4R-tauopathy" showed high specificity and may be suitable for the recruitment of patients with progressive supranuclear palsy and corticobasal degeneration into therapeutic trials targeting 4R-tauopathy. The low sensitivity underpins the need for diagnostic biomarkers. © 2019 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category "probable 4-repeat (4R)-tauopathy" for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration.
OBJECTIVES
To validate the accuracy of these clinical criteria for "probable 4R-tauopathy" to predict underlying 4R-tauopathy pathology.
METHODS
Diagnostic accuracy for 4R-tauopathies according to the established criteria was estimated retrospectively in autopsy-confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R-tauopathies), and Parkinson's disease, multiple system atrophy, and frontotemporal lobar degeneration (grouped as non-4R-tauopathies).
RESULTS
We identified 250 cases with progressive supranuclear palsy (N = 195) and corticobasal degeneration (N = 55) and with and non-4R-tauopathies (N = 161). Sensitivity and specificity of "probable 4R-tauopathy" was 10% and 99% in the first year and 59% and 88% at final record.
CONCLUSIONS
The new diagnostic category "probable 4R-tauopathy" showed high specificity and may be suitable for the recruitment of patients with progressive supranuclear palsy and corticobasal degeneration into therapeutic trials targeting 4R-tauopathy. The low sensitivity underpins the need for diagnostic biomarkers. © 2019 International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 31571273
doi: 10.1002/mds.27872
pmc: PMC7993399
mid: NIHMS1678163
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-176Subventions
Organisme : NIA NIH HHS
ID : P30 AG010124
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG066597
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS109260
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG062418
Pays : United States
Organisme : Medical Research Council
ID : MR/L016397/1
Pays : United Kingdom
Investigateurs
Ikuko Aiba
(I)
Angelo Antonini
(A)
Thomas Arzberger
(T)
Paolo Barone
(P)
Kailash P Bhatia
(KP)
Adam K Boxer
(AK)
Carlo Colosimo
(C)
Yaroslau Compta
(Y)
Jean Christophe Corvol
(JC)
Dennis W Dickson
(DW)
Ellen Gelpi
(E)
Armin Giese
(A)
Lawrence I Golbe
(LI)
Murray Grossman
(M)
Günter U Höglinger
(GU)
Franziska Hopfner
(F)
David J Irwin
(DJ)
Keith A Josephs
(KA)
Jan Kassubek
(J)
Gabor G Kovacs
(GG)
Anthony E Lang
(AE)
Johannes Levin
(J)
Irene Litvan
(I)
Matthias Höllerhage
(M)
Nikolaus McFarland
(N)
Wassilios G Meissner
(WG)
Huw R Morris
(HR)
Ulrich Müller
(U)
Christer Nilsson
(C)
Wolfgang H Oertel
(WH)
Alexander Pantelyat
(A)
Alex Rajput
(A)
Gesine Respondek
(G)
James B Rowe
(JB)
Ruji Sakakibara
(R)
Gerard Schellenberg
(G)
Maria Stamelou
(M)
Claire Troakes
(C)
Thilo van Eimeren
(T)
John C van Swieten
(JC)
Gregor K Wenning
(GK)
Jennifer L Whitwell
(JL)
Informations de copyright
© 2019 International Parkinson and Movement Disorder Society.
Références
Mov Disord Clin Pract. 2018 Mar 06;5(2):141-144
pubmed: 30363409
Mov Disord. 2019 Aug;34(8):1144-1153
pubmed: 30726566
Neurology. 1994 Nov;44(11):2015-9
pubmed: 7969952
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
Neuropathol Appl Neurobiol. 2015 Feb;41(1):3-23
pubmed: 25495175
J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):925-9
pubmed: 24521567
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
J Neuropathol Exp Neurol. 2002 Nov;61(11):935-46
pubmed: 12430710
Acta Neuropathol. 2010 Jan;119(1):1-4
pubmed: 19924424
Prog Neurobiol. 2019 Sep;180:101644
pubmed: 31238088
Mov Disord. 2019 Aug;34(8):1228-1232
pubmed: 30884545
J Neurol. 1999 Sep;246 Suppl 2:II6-15
pubmed: 10525997
Brain. 2010 Jul;133(Pt 7):2045-57
pubmed: 20584946
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Lancet Neurol. 2009 Dec;8(12):1150-7
pubmed: 19909913
Neuropathol Appl Neurobiol. 2007 Dec;33(6):615-20
pubmed: 17990994
Mov Disord. 2014 Dec;29(14):1758-66
pubmed: 25370486